Literature DB >> 7526884

Oestrogen and epidermal growth factor down-regulate erbB-2 oncogene protein expression in breast cancer cells by different mechanisms.

S Antoniotti1, D Taverna, P Maggiora, M L Sapei, N E Hynes, M De Bortoli.   

Abstract

Mitogen-induced mammary cell growth is often accompanied by decreased levels of expression of the p185erbB-2 protein. We have previously reported that oestrogen inhibits erbB-2 mRNA and protein expression in breast cancer cells, while epidermal growth factor (EGF) treatment has been shown to decrease p185erbB-2 levels in normal mouse mammary epithelial cells. In the present work, we studied the effect of oestrogen and EGF on erbB-2 expression in oestrogen-responsive breast cancer cells. We observed that both oestrogen and EGF comparably down-regulated p185erbB-2 levels, while stimulating growth of T47D and ZR75.1 cells. Oestrogens, but not EGF, concomitantly down-regulated erbB-2 mRNA. Run-on analysis showed a reduced erbB-2 transcription rate in the presence of oestrogens. Furthermore, the transcriptional activity of a 219 bp proximal fragment of the human erbB-2 promoter was repressed by oestrogens, whereas it was enhanced by EGF. EGF stimulated both tyrosine phosphorylation and autokinase activity of p185erbB-2 down-regulates p185erbB-2 at a post-translational level. Thus, two factors converging in terms of effects on cell growth, display divergent mechanisms of regulation of erbB-2 expression.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7526884      PMCID: PMC2033707          DOI: 10.1038/bjc.1994.454

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  44 in total

1.  Proto-oncogene amplification and human breast tumor phenotype.

Authors:  J Adnane; P Gaudray; M P Simon; J Simony-Lafontaine; P Jeanteur; C Theillet
Journal:  Oncogene       Date:  1989-11       Impact factor: 9.867

2.  Expression of the c-erbB-2 protein in normal and transformed cells.

Authors:  W J Gullick; M S Berger; P L Bennett; J B Rothbard; M D Waterfield
Journal:  Int J Cancer       Date:  1987-08-15       Impact factor: 7.396

3.  Human HER2 (neu) promoter: evidence for multiple mechanisms for transcriptional initiation.

Authors:  M Tal; C R King; M H Kraus; A Ullrich; J Schlessinger; D Givol
Journal:  Mol Cell Biol       Date:  1987-07       Impact factor: 4.272

4.  Heterogeneous expression of erbB-2 messenger RNA in human breast cancer.

Authors:  C R King; S M Swain; L Porter; S M Steinberg; M E Lippman; E P Gelmann
Journal:  Cancer Res       Date:  1989-08-01       Impact factor: 12.701

5.  Transcriptional repression of the neu protooncogene by estrogen stimulated estrogen receptor.

Authors:  K S Russell; M C Hung
Journal:  Cancer Res       Date:  1992-12-01       Impact factor: 12.701

6.  Tamoxifen up-regulates c-erbB-2 expression in oestrogen-responsive breast cancer cells in vitro.

Authors:  S Antoniotti; P Maggiora; C Dati; M De Bortoli
Journal:  Eur J Cancer       Date:  1992       Impact factor: 9.162

7.  erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells.

Authors:  P P Di Fiore; J H Pierce; M H Kraus; O Segatto; C R King; S A Aaronson
Journal:  Science       Date:  1987-07-10       Impact factor: 47.728

8.  Differential effects of phorbol ester on epidermal growth factor receptors in estrogen receptor-positive and -negative breast cancer cell lines.

Authors:  M Koga; E A Musgrove; R L Sutherland
Journal:  Cancer Res       Date:  1990-08-15       Impact factor: 12.701

9.  Structure and inducible regulation of the human c-erb B2/neu promoter.

Authors:  L G Hudson; A P Ertl; G N Gill
Journal:  J Biol Chem       Date:  1990-03-15       Impact factor: 5.157

10.  Overexpression of the EGF receptor-related proto-oncogene erbB-2 in human mammary tumor cell lines by different molecular mechanisms.

Authors:  M H Kraus; N C Popescu; S C Amsbaugh; C R King
Journal:  EMBO J       Date:  1987-03       Impact factor: 11.598

View more
  9 in total

Review 1.  Hormonal regulation of type I receptor tyrosine kinase expression in the mammary gland.

Authors:  M De Bortoli; C Dati
Journal:  J Mammary Gland Biol Neoplasia       Date:  1997-04       Impact factor: 2.673

2.  Prognostic value of epidermal growth factor expression in breast cancer.

Authors:  R Pirinen; P Lipponen; S Aaltomaa; K Syrjänen
Journal:  J Cancer Res Clin Oncol       Date:  1997       Impact factor: 4.553

Review 3.  Oncogenes and tumor suppressor genes.

Authors:  Eva Y H P Lee; William J Muller
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-08-18       Impact factor: 10.005

4.  Genistein affects HER2 protein concentration, activation, and promoter regulation in BT-474 human breast cancer cells.

Authors:  Mary S Sakla; Nader S Shenouda; Pete J Ansell; Ruth S Macdonald; Dennis B Lubahn
Journal:  Endocrine       Date:  2007-10-02       Impact factor: 3.633

5.  Activator protein-2gamma (AP-2gamma) expression is specifically induced by oestrogens through binding of the oestrogen receptor to a canonical element within the 5'-untranslated region.

Authors:  Francesca Orso; Erika Cottone; Mark D Hasleton; J Claire Ibbitt; Piero Sismondi; Helen C Hurst; Michele De Bortoli
Journal:  Biochem J       Date:  2004-01-15       Impact factor: 3.857

6.  A mechanistic study of the effect of doxorubicin/adriamycin on the estrogen response in a breast cancer model.

Authors:  Jessica E Pritchard; Patrick M Dillon; Mark R Conaway; Corinne M Silva; Sarah J Parsons
Journal:  Oncology       Date:  2012-09-05       Impact factor: 2.935

7.  Steroid receptor coactivators, HER-2 and HER-3 expression is stimulated by tamoxifen treatment in DMBA-induced breast cancer.

Authors:  Line L Haugan Moi; Marianne Hauglid Flågeng; Jennifer Gjerde; Andre Madsen; Therese Halvorsen Røst; Oddrun Anita Gudbrandsen; Ernst A Lien; Gunnar Mellgren
Journal:  BMC Cancer       Date:  2012-06-15       Impact factor: 4.430

8.  Human epidermal growth factor receptor 2 and estrogen receptor status in respect to tumor characteristics in non-metastatic breast cancer.

Authors:  Hanifeh Mirtavoos-Mahyari; Adnan Khosravi; Zahra Esfahani-Monfared
Journal:  Tanaffos       Date:  2014

9.  miR-21 Expression in Cancer Cells may Not Predict Resistance to Adjuvant Trastuzumab in Primary Breast Cancer.

Authors:  Boye Schnack Nielsen; Eva Balslev; Tim Svenstrup Poulsen; Dorte Nielsen; Trine Møller; Christiane Ehlers Mortensen; Kim Holmstrøm; Estrid Høgdall
Journal:  Front Oncol       Date:  2014-08-15       Impact factor: 6.244

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.